The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
diarrhea, and abdominal pain. While these symptoms are usually short-lived, they can be severe and debilitating. Systemic Infections Certain pathogens can spread beyond the digestive tract and cause ...
Some 2million Americans suffer from celiac disease — where gluten causes severe damage to the gut. Sufferers of the disease experience an extreme immune reaction after eating the protein, causing a ...
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...